Tenapanor Monotherapy effectively treats hyperphosphatemia in dialysis patients: Study

Published On 2021-10-25 03:30 GMT   |   Update On 2021-10-25 03:30 GMT

According to a recent study presented at the 58th European Renal Association-European Dialysis and Transplant Association meeting, tenapanor efficiently cures hyperphosphatemia in dialysis patients, whether administered alone or in conjunction with phosphate binders.

This is a randomized, open-label research to compare alternative strategies of starting tenapanor medication in CKD dialysis patients with hyperphosphatemia who are either phosphate binder naïve or on phosphate binder therapy. 

The study was conducted by Steven Fishbane and team and it's findings  were presented in the U.S National Library of Medicine on 16th September, 2021.

The goal of this study is to see if tenapanor alone or in combination with phosphate binders can achieve target serum phosphorus (s-P) levels of 5.5 mg/dL when used as the core therapy (alone or in combination with phosphate binders) for the treatment of hyperphosphatemia in patients on dialysis with chronic kidney disease (CKD). The trial included a Screening visit as well as a 10-week open-label Treatment Period (TP). Tenapanor was administered to patients during the TP at a dose of 30 mg twice daily. Tenapanor was given twice a day, before breakfast and supper.

Interim data from the OPTIMIZE study (Open-Label Study to Evaluate Potential Real-World Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis; NCT04549597) showed that over 10 weeks, two-thirds of binder-naïve patients who started on tenapanor monotherapy achieved or maintained target phosphorus levels of less than 5.5 mg/dL. Tenapanor helped roughly half of the patients attain target phosphorus levels with or without the use of reduced-dose phosphate binders.


In conclusion, Tenapanor inhibits the intestinal sodium/hydrogen exchanger 3, tightening epithelial cell junctions and decreasing phosphate permeability. Tenapanor's initial dose in this experiment was 30 mg twice a day, although it might be reduced for greater gastrointestinal tolerability.



Article Source : U.S National Library of Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News